2020 ICD-10-CM Diagnosis Code D47.1

Chronic myeloproliferative disease

    2016 2017 2018 2019 2020 Billable/Specific Code
  • D47.1 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
  • The 2020 edition of ICD-10-CM D47.1 became effective on October 1, 2019.
  • This is the American ICD-10-CM version of D47.1 - other international versions of ICD-10 D47.1 may differ.
Applicable To
  • Chronic neutrophilic leukemia
  • Myeloproliferative disease, unspecified
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as D47.1. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • atypical chronic myeloid leukemia BCR/ABL-negative (
    ICD-10-CM Diagnosis Code C92.2

    Atypical chronic myeloid leukemia, BCR/ABL-negative

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    C92.2-
    )
  • chronic myeloid leukemia BCR/ABL-positive (
    ICD-10-CM Diagnosis Code C92.1

    Chronic myeloid leukemia, BCR/ABL-positive

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Applicable To
    • Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive
    • Chronic myelogenous leukemia, t(9;22) (q34;q11)
    • Chronic myelogenous leukemia with crisis of blast cells
    Type 1 Excludes
    • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
    • chronic myelomonocytic leukemia (C93.1-)
    • chronic myeloproliferative disease (D47.1)
    C92.1-
    )
  • myelofibrosis NOS (
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
    D75.81
    )
  • myelophthisic anemia (
    ICD-10-CM Diagnosis Code D61.82

    Myelophthisis

      2016 2017 2018 2019 2020 Billable/Specific Code
    Applicable To
    • Leukoerythroblastic anemia
    • Myelophthisic anemia
    • Panmyelophthisis
    Code Also
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    • tuberculosis (A15.-)
    Type 1 Excludes
    • idiopathic myelofibrosis (D47.1)
    • myelofibrosis NOS (D75.81)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • primary myelofibrosis (D47.1)
    • secondary myelofibrosis (D75.81)
    D61.82
    )
  • myelophthisis (
    ICD-10-CM Diagnosis Code D61.82

    Myelophthisis

      2016 2017 2018 2019 2020 Billable/Specific Code
    Applicable To
    • Leukoerythroblastic anemia
    • Myelophthisic anemia
    • Panmyelophthisis
    Code Also
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    • tuberculosis (A15.-)
    Type 1 Excludes
    • idiopathic myelofibrosis (D47.1)
    • myelofibrosis NOS (D75.81)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • primary myelofibrosis (D47.1)
    • secondary myelofibrosis (D75.81)
    D61.82
    )
  • secondary myelofibrosis NOS (
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
    D75.81
    )
The following code(s) above D47.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to D47.1:
  • C00-D49
    2020 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • D37-D48
    2020 ICD-10-CM Range D37-D48

    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes

    Note
    • Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
    Type 1 Excludes
    • neoplasms of unspecified behavior (D49.-)
    Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes
Approximate Synonyms
  • Chronic myeloproliferative disorder (clinical)
  • Myeloproliferative disorder, chronic
Clinical Information
  • A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (who 2008)
  • A disease in which too many neutrophils (a type of white blood cell) are found in the blood. The extra neutrophils may cause the spleen and liver to become enlarged. Chronic neutrophilic leukemia may stay the same for many years or it may progress quickly to acute leukemia.
  • A group of slow growing blood cancers, including chronic myelogenous leukemia, in which large numbers of abnormal red blood cells, white blood cells, or platelets grow and spread in the bone marrow and the peripheral blood.
  • A rare chronic myeloproliferative neoplasm characterised by neutrophilic leukocytosis. There is no detectable philadelphia chromosome or bcr/abl fusion gene.
  • A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, eosinophilia, or basophilia is present, nor is there a philadelphia chromosome or bcr-abl fusion gene (genes, abl).
  • Abnormal proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential.
  • Chronic myeloproliferative disorders (cmpds) are clonal hematopoietic stem cell disorders, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, and megakaryocytic) lineages. The proliferation is associated with relatively normal, effective maturation, resulting in increased numbers of granulocytes, red blood cells, and/or platelets in the peripheral blood. Cmpds are primarily diseases of adults.
  • Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent myeloid progenitor cells, most often caused by a mutation in the jak2 protein tyrosine kinase.
ICD-10-CM D47.1 is grouped within Diagnostic Related Group(s) (MS-DRG v37.0):
  • 820 Lymphoma and leukemia with major o.r. Procedure with mcc
  • 821 Lymphoma and leukemia with major o.r. Procedure with cc
  • 822 Lymphoma and leukemia with major o.r. Procedure without cc/mcc
  • 823 Lymphoma and non-acute leukemia with other procedure with mcc
  • 824 Lymphoma and non-acute leukemia with other procedure with cc
  • 825 Lymphoma and non-acute leukemia with other procedure without cc/mcc
  • 840 Lymphoma and non-acute leukemia with mcc
  • 841 Lymphoma and non-acute leukemia with cc
  • 842 Lymphoma and non-acute leukemia without cc/mcc

Convert D47.1 to ICD-9-CM

Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
Code annotations containing back-references to D47.1:
  • Code Also: D47.02
    ICD-10-CM Diagnosis Code D47.02

    Systemic mastocytosis

      2018 - New Code 2019 2020 Billable/Specific Code
    Applicable To
    • Indolent systemic mastocytosis
    • Isolated bone marrow mastocytosis
    • Smoldering systemic mastocytosis
    • Systemic mastocytosis, with an associated hematological non-mast cell lineage disease (SM-AHNMD)
    Code Also
    • , if applicable, any associated hematological non-mast cell lineage disease, such as:
    • acute myeloid leukemia (C92.6-, C92.A-)
    • chronic myelomonocytic leukemia (C93.1-)
    • essential thrombocytosis (D47.3)
    • hypereosinophilic syndrome (D72.1)
    • myelodysplastic syndrome (D46.9)
    • myeloproliferative syndrome (D47.1)
    • non-Hodgkin lymphoma (C82-C85)
    • plasma cell myeloma (C90.0-)
    • polycythemia vera (D45)
    Type 1 Excludes
    • aggressive systemic mastocytosis (C96.21)
    • mast cell leukemia (C94.3-)
  • Type 1 Excludes: C92.1
    , D61.81
    , D61.82
    , D61.82
    , D75.81
    , D75.81
    ICD-10-CM Diagnosis Code C92.1

    Chronic myeloid leukemia, BCR/ABL-positive

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Applicable To
    • Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive
    • Chronic myelogenous leukemia, t(9;22) (q34;q11)
    • Chronic myelogenous leukemia with crisis of blast cells
    Type 1 Excludes
    • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
    • chronic myelomonocytic leukemia (C93.1-)
    • chronic myeloproliferative disease (D47.1)
    ICD-10-CM Diagnosis Code D61.81

    Pancytopenia

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    Type 1 Excludes
    • pancytopenia (due to) (with) aplastic anemia (D61.9)
    • pancytopenia (due to) (with) bone marrow infiltration (D61.82)
    • pancytopenia (due to) (with) congenital (pure) red cell aplasia (D61.01)
    • pancytopenia (due to) (with) hairy cell leukemia (C91.4-)
    • pancytopenia (due to) (with) human immunodeficiency virus disease (B20.-)
    • pancytopenia (due to) (with) leukoerythroblastic anemia (D61.82)
    • pancytopenia (due to) (with) myeloproliferative disease (D47.1)
    Type 2 Excludes
    • pancytopenia (due to) (with) myelodysplastic syndromes (D46.-)
    ICD-10-CM Diagnosis Code D61.82

    Myelophthisis

      2016 2017 2018 2019 2020 Billable/Specific Code
    Applicable To
    • Leukoerythroblastic anemia
    • Myelophthisic anemia
    • Panmyelophthisis
    Code Also
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    • tuberculosis (A15.-)
    Type 1 Excludes
    • idiopathic myelofibrosis (D47.1)
    • myelofibrosis NOS (D75.81)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • primary myelofibrosis (D47.1)
    • secondary myelofibrosis (D75.81)
    ICD-10-CM Diagnosis Code D61.82

    Myelophthisis

      2016 2017 2018 2019 2020 Billable/Specific Code
    Applicable To
    • Leukoerythroblastic anemia
    • Myelophthisic anemia
    • Panmyelophthisis
    Code Also
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    • tuberculosis (A15.-)
    Type 1 Excludes
    • idiopathic myelofibrosis (D47.1)
    • myelofibrosis NOS (D75.81)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • primary myelofibrosis (D47.1)
    • secondary myelofibrosis (D75.81)
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)

Diagnosis Index entries containing back-references to D47.1:
  • Disease, diseased - see also Syndrome
    • myeloproliferative, not classified C94.6
      ICD-10-CM Diagnosis Code C94.6

      Myelodysplastic disease, not classified

        2016 2017 2018 2019 2020 Billable/Specific Code
      Applicable To
      • Myeloproliferative disease, not classified
      • chronic D47.1
  • Leukemia, leukemic C95.9-
    ICD-10-CM Diagnosis Code C95.9-

    Leukemia, unspecified

      2016 2017 2018 2019 2020 Non-Billable/Non-Specific Code
    • chronic neutrophilic D47.1
  • Myelofibrosis D75.81
    ICD-10-CM Diagnosis Code D75.81

    Myelofibrosis

      2016 2017 2018 2019 2020 Billable/Specific Code Manifestation Code
    Applicable To
    • Myelofibrosis NOS
    • Secondary myelofibrosis NOS
    Code First
    • the underlying disorder, such as:
    • malignant neoplasm of breast (C50.-)
    Type 1 Excludes
    • acute myelofibrosis (C94.4-)
    • idiopathic myelofibrosis (D47.1)
    • leukoerythroblastic anemia (D61.82)
    • myelofibrosis with myeloid metaplasia (D47.4)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • primary myelofibrosis (D47.1)
    Use Additional
    • code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
    • primary D47.1
  • Myelosis
    • chronic D47.1
  • Syndrome - see also Disease
    • myeloproliferative D47.1 (chronic)

ICD-10-CM Codes Adjacent To D47.1
D46.B Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.C Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality
D46.4 Refractory anemia, unspecified
D46.Z Other myelodysplastic syndromes
D46.9 Myelodysplastic syndrome, unspecified
D47 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.0 Mast cell neoplasms of uncertain behavior
D47.01 Cutaneous mastocytosis
D47.02 Systemic mastocytosis
D47.09 Other mast cell neoplasms of uncertain behavior
D47.1 Chronic myeloproliferative disease
D47.2 Monoclonal gammopathy
D47.3 Essential (hemorrhagic) thrombocythemia
D47.4 Osteomyelofibrosis
D47.Z Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.Z1 Post-transplant lymphoproliferative disorder (PTLD)
D47.Z2 Castleman disease
D47.Z9 Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue
D47.9 Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified
D48 Neoplasm of uncertain behavior of other and unspecified sites
D48.0 Neoplasm of uncertain behavior of bone and articular cartilage

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.